Tvardi reports 2025 net loss $18.2M; cash to fund into Q4 2026; key clinical milestones ahead

Tvardi Therapeutics, Inc.

2026-Q1 EPS reported -$0.73

Net loss for 2025 was $18.2M ($2.46 basic EPS); cash $30.8M expected to fund operations into Q4 2026.
R&D expenses decreased to $18.0M in 2025 from $23.7M in 2024, driven by lower TTI-101 clinical costs.
Phase 2 IPF trial of TTI-101 showed 9.4% fibrosis reduction vs 2.4% placebo; IL-6 declined 4.5-fold.
Topline data from TTI-109 healthy volunteer study expected Q2 2026; TTI-101 HCC Phase 2 data in H2 2026.
G&A expenses rose to $8.7M in 2025 from $4.5M in 2024 due to merger-related professional fees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil, EPS Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas.

Period: the fourth quarter and full-year ended December 31, 2025
Net income: Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil
EPS: Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas
Result: reported results

Exact text from the filing

On March 31, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter and year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-037724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.